{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:45:27Z","timestamp":1764603927679,"version":"3.44.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.semarthrit.2023.152175","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:20:38Z","timestamp":1676341238000},"page":"152175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b\/tsDMARDs: A systematic review"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-2384","authenticated-orcid":false,"given":"Wendy","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Morand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152175_bib0001","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0003","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: a literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0005","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0007","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"10.1016\/j.semarthrit.2023.152175_bib0009","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152175_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous Secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152175_bib0012","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152175_bib0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0014","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0015","first-page":"480","article-title":"The efficacy and safety of netakimab in patients with psoriatic arthritis: results from the Phase III clinical study PATERA","volume":"58","author":"Korotaeva","year":"2020","journal-title":"Nauchno-prakt Revmatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152175_bib0016","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152175_bib0017","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0018","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152175_bib0019","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152175_bib0020","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0021","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152175_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152175_bib0023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"10.1016\/j.semarthrit.2023.152175_bib0024","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0025","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0027","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0028","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0029","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0031","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152175_bib0032","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebocontrolled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (United Kingdom)"},{"issue":"16","key":"10.1016\/j.semarthrit.2023.152175_bib0033","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.semarthrit.2023.152175_bib0034","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0036","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: sELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.semarthrit.2023.152175_bib0037","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0038","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152175_bib0039","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10903-015-0198-9","article-title":"A review of barriers to minorities\u2019 participation in cancer clinical trials: implications for future cancer research","volume":"18","author":"Salman","year":"2016","journal-title":"J Immigr Minor Health"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0041","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cncr.28575","article-title":"Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0042","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","article-title":"Challenging assumptions about minority participation in US clinical research","volume":"101","author":"Fisher","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0043","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.211330","article-title":"Promoting diversity, equity, and inclusion for psoriatic diseases","author":"Takeshita","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0044","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10067-014-2763-3","article-title":"Psoriasis and psoriatic arthritis in African-American patients\u2014The need to measure disease burden","volume":"34","author":"Kerr","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2368","article-title":"Rheumatic diseases in China","volume":"10","author":"Zeng","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0046","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/rheumatology\/keaa298","article-title":"A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds","volume":"60","author":"Aslam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14745","article-title":"Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review","volume":"2","author":"Strait","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-018-0728-2","article-title":"The representation of gender and race\/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus","volume":"20","author":"Falasinnu","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0049","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3899\/jrheum.200371","article-title":"Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Ogdie","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0050","article-title":"Assessment of changes in diversity in dermatology clinical trials between 2010-2015 and 2015-2020: a systematic review","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"year":"2020","series-title":"Enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs: guidance for industry","key":"10.1016\/j.semarthrit.2023.152175_bib0051"},{"key":"10.1016\/j.semarthrit.2023.152175_bib0052","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/rheumatology\/keab774","article-title":"Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis","volume":"61","author":"Erre","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722300015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722300015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:37Z","timestamp":1758733777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722300015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":52,"alternative-id":["S004901722300015X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152175","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b\/tsDMARDs: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152175"}}